

12th October 2020

ASX Announcement CEO appointment

Lifespot Health Limited (ASX: LSH) ("the Company") is pleased to announce the appointment of Matthew Golden to the role of Chief Executive Officer effective immediately.

Matthew is a commercial healthcare Professional with almost 20 years' experience in the pharmaceutical industry both in Australian and international markets working primarily at Pfizer Pharmaceuticals and Medical Developments International.

Matthew has a strong track record of successful local and international new product launches and established products sales growth as well as the development and launch of digital marketing initiatives in both Australian and international markets.

At Medical Developments International (MDI) Matthew drove sales of a range of products in the areas of pain management, asthma and resuscitation, including the global supply of Penthrox, often known as the "Green Whistle", for Acute pain relief.

His academic qualifications include Master of Marketing and Bachelor of Science Degree, both from Monash University in addition to courses in leadership, management and software programming.

Matthew's immediate priorities will be to review the Company's telehealth and medical cannabis inhaler strategies, make recommendations to the Board and clearly define the milestones and timing of the Company's Medihale inhaler device clinical safety and pharmacokinetic trials.

The key terms of Mr. Golden's CEO appointment are summarised below:

Base Remuneration	\$180,000 per annum, plus superannuation payments required under Australian law.
Short & Long Term Incentive	The Company may also award share-based and bonus-based payments as short-term and long-term incentives which will be linked to the achievement of milestones to be determined and agreed in due course, and subject to any applicable shareholder approval requirements.
Termination	3 months' notice by either party or less by mutual agreement.
Other terms	Other terms of employment as are standard under Australian law for a position of this nature.



Effective immediately, Rodney Hannington and Frank Cannavo will transition from their previous executive roles to resume their Non-Executive Chairman and Non-Executive Director roles respectively.

The Company will provide further updates in due course.

Authorised by the Board of Directors.

Justyn Stedwell Company Secretary (03) 8395 5446